By Mary de Wet
Gemini Therapeutics shares were up 18% at $1.83 in premarket trading Tuesday after its merger target, Disc Medicine Inc., received orphan drug designation for bitopertin.
The stock is down about 47% for the year.
Gemini Therapeutics said in August that it agreed to merge with the clinical-stage biopharmaceutical company in a stock swap that would result in Disc shareholders owning more than 70% of the combined company.
On Tuesday, Disc said the Food and Drug Administration had given the designation to bitopertin to treat erythropoietic protoporphyria, a rare disease that causes severe reactions when patients are exposed to sunlight.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S., and provides for an extended marketing exclusivity period against competition.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
December 27, 2022 08:26 ET (13:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。